Actinium Pharmaceuticals, Inc. (delaware) · AMEX:ATNM
Actinium Pharmaceuticals, Inc. (delaware) — Actinium Pharmaceuticals — LD Micro Conference (December 2013)
21 slides from Actinium Pharmaceuticals, Inc. (delaware)'s conference presentation, Dec 9, 2013
Slide 1: Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. 4 » December 5, 2013 LD Micro Conference Trading Symbol: ATNM
Slide 2: Disclaimer and Safe Harbor Statement
Disclaimer and Safe Harbor Statement Disclaimer ‘The contents of this presentation and the information which you are given at the time of these slides and the presentation have not been approved bby an authorized person within the meaning of the Financial Services and Markets Act 2000 (the “Act’), R
Slide 3: Company Description
Company Description A public biotechnology company using world class science to develop and commercialize antibody directed radioisotopes to target unmet medical needs in cancer.
Slide 4: Company Overview
Company Overview Y Prior clinical data for both Iomab-B and Actimab-A favor successful trial results Y Breakthrough therapy potential implies successful market penetration for both Iomab-B and Actimab-A Y APIT platform poised to deliver multiple blockbuster cancer drugs v An expert team possessing t
Slide 5: Core Team & Advisors
Core Team & Advisors team Kaushik J. Dave, PhD, MBA. President and CEO 25 years of pharmacentical and biotechnology industry experience at large pharmaceutical companies and small startops. * Formedy, EVP at Antares Phasna Inc., VP at Palatin Technologies Inc, and Big Phacma Gchesing Plough and Mesc
Slide 6: Clinical Advisory Board
Clinical Advisory Board ‘Memorial Sloan Kettering Cancer Center Fred Hutchinson Cancer Center ‘MD Anderson Cancer Center Johns Hopkins Medicine University of Pennsylvania Health System. xX ACT PHUPOLACEUTEALS David Scheinberg, MD., PhD (Gsenan of Expecmental Therpeatier st MSKCC ‘VineestAstoe Gir Sc
Slide 7: Antibody Approaches Targeting Cancer Cells
Antibody Approaches Targeting Cancer Cells Opportunity Cancer Treatment Options Radision ‘Moncclonal Ansbodies (mAbs) Treatment % 80% ¢ External radiation majsity weamest —<10% # Abvays apharmacentical ¢ Intemnal radiation has mostiy no IP + Sxomg IP protection <3% + Commoditized ~30% © Mostly propr
Slide 8: ATNM's Proprietary Technology Platform
ATNM’s Proprietary Technology Platform SY <+——. Antibody (targeting agent) Chelator (linker) @<s— «/ (* emitter (killing agent) * 68 Patents issued and pending, United States 17, International 51 ¢ Eligible for orphan drug exclusivity IP encompases core aspects of drug preparation, production, compo
Slide 9: ATNM's Product Pipeline
ATNM’s Product Pipeline Tomab-B Bismab-A Actimab-A (s.d. Actimab-A (fd) 119-A225° Actimab-B Actimab-C Actimab-P Indicati BMT Bone Massow Teansplant) AML (Acate Myeloid Leukemia) AML AML GBM, Breast Canc: BMT Colon Cancer Prostate Cancer Development Status sd. —single dose £d_— fractionated dose 2) D
Slide 10: Iomab-B Overview
Iomab-B Overview * Breakthrough therapy for BMT conditioning especially for elderly, very sick patients with few curative treatment options — Initial indication is relapsed and refractory AML patients over 55 years old ¢ Compelling clinical data from proof of concept trial in elderly refractory and
Slide 11: Iomab-B Program Overview
Iomab-B Program Overview Extensive safety and efficacy across multiple indications inical Trials* N AML, MDS, ALL 34 AML>1* remission 23 AML 1* remission 43 (16-50) High-risk MDS, 68in dose advanced AML (50+) escalation, 31 treated at MTD High-risk MDS, 14 in dose AML (18-50) escalation High-risk MD
Slide 12: Iomab-B Phase I/II Results
Iomab-B Phase I/II Results Compelling clinical results enable pivotal Phase III trial * — Non-relapse mortality (NRM) Day 100: 10% Complete response rate: 100% — Overall: 20% (NRM = 46% in comparable : Ae patients with myeloablative conditioning) * Engraftment by day 28: 100% ¢ Transplant related mo
Slide 13: Iomab-B FDA Meeting Results
Iomab-B FDA Meeting Results # A successful End of Phase II meeting was held with the FDA and agreements were reached on the following — Path to approval — Number of studies — Phase III trial design to support a BLA submission ~ Patient population — Study size (n) — Primary and secondary endpoints —
Slide 14: Iomab-B Development Plan
Iomab-B Development Plan Currently no approved treatments for Iomab-B targeted patients imply blockbuster potential i o pen . ses a Total $4,098 ~Phase Iand Phase II zepeesent physician tral at Feed Hutchison Cancer Research Center. Phase III trials epresent ATNM sponsorship. Source: GLOBOCAN, SEER,
Slide 15: Iomab-B A New Treatment Paradigm
Iomab-B A New Treatment Paradigm Y Provides treatment alternative to patients with no options Y Significantly expands patient population eligible for BMT Y Provides faster, safer way of performing bone marrow transplant Y Minimizes transplant related mortality Y Significantly increases curative outc
Slide 16: Bismab-A Em Actimab-A
Bismab-A Em Actimab-A Bismab-A experience implies successful Actimab-A trial results as an induction therapy in elderly AML 1st Generation 2nd Generation Effectiveness: ¢ Proof of concept in humans + 500s more potent than Bismab-A Supply Chain: ¢ Complex, high COGS + Simple, 10x lower COGS Ease of U
Slide 17: Actimab-A Clinical Trial Update
Actimab-A Clinical Trial Update # Started the new multicenter Phase I/TI clinical trial ¢ Expanded the number of participating clinical centers: — Memorial Sloan Kettering Cancer Center, Johns Hopkins Medicine, Fred Hutchinson Cancer Center, University of Pennsylvania Health Center, MD Anderson Canc
Slide 18: Market Potential of Product Pipeline
ii er Indication 4" Bone Marrow Transplant (BMT) 2 Acute Myeloid Leukemia (AML) ms Glioblastoma Multiforme (GBM) “ Prostate Cancer (metastatic) ‘Metastatic Colorectal Cancer 536,000 Tees mesos BY wit Market Potential of Product Pipeline Target Popula 241,200 $4,824 ‘Madket Potential calculated based
Slide 19: Near-term Value Drivers
Near-term Value Drivers Muttiple milestones in next 12-18 months ¢ Iomab-B * Uplisting to NASDAQ / NYSE MKT — Complete Phase III Protocol — Start cGMP mAb mfg % Additional Analyst Coverage — Start drug mfg cGMP process — Complete cGMP mAb mfz * Collaborations — Complete Drug mfg GMP — Submit Phase I
Slide 20: Company Overview
Company Overview Y Prior clinical data for both Iomab-B and Actimab-A favor successful trial results Y Breakthrough therapy potential implies successful market penetration for both Iomab-B and Actimab-A Y APIT platform poised to deliver multiple blockbuster cancer drugs v An expert team possessing t
Slide 21: Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. 4 » December 5, 2013 LD Micro Conference Trading Symbol: ATNM
Actinium Pharmaceuticals — LD Micro Conference (December 2013) on 6ix